Fetal Renal Artery Doppler in Patients With Preeclampsia and Its Role in Prediction of Adverse Neonatal Outcomes
Data Collection
Collected at a single point in time - Cross-sectionalUrogenital Diseases+2
+ Female Urogenital Diseases and Pregnancy Complications
+ Pre-Eclampsia
Other
Utilizing specific methods not covered by standard models in order to address unique research questions.Summary
Study start date: November 1, 2023
Actual date on which the first participant was enrolled.Preeclampsia is a major devastating medical condition that affects pregnant women after 20 weeks of pregnancy. It affects 2:10% of pregnancies worldwide according to World Health Organisation with higher incidence in developing countries. Vascular endothelial dysfunction due to abnormal placentation is believed to be the main cause of multi-organ failure and uteroplacental insufficiency that occur in preeclampsia leading to major adverse effects in both mother and fetus. Placental insufficiency causes a redistribution of fetal blood to essential organs ; brain, heart and adrenal glands by decreasing their vascular resistance on expense of peripheral organs such as kidney which exhibit increased vascular resistance and impaired perfusion. This is in contrast to normal pregnancies near term in which renal vascular resistance falls and increased blood flow to the kidneys is observed. Doppler ultrasound examination of vasculature of selected organs such as kidneys may have a role in detection of hemodynamic rearrangements that occur in cases of placental insufficiency and preeclampsia.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.88 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * a) Preeclampsia: * Women with preeclampsia \>28 weeks of pregnancy. * Singleton pregnancy. * Women with intrauterine growth restriction and abnormal amniotic fluid volume to simulate real world data. b) Control: * Women with healthy pregnancy matched by closest gestational age. Exclusion Criteria: * ● Multiple pregnancy. * Known Congenital fetal malformations. * Women with other comorbidity such as ischemic heart disease, DM, Autoimmune disorders, kidney disease, neurological disorders, liver or haematological disorders. * Women unable to provide informed consent. * Women who refuse to participate
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location